Primary Health Net
Back to Home
 
Equipment
Grafton Optical
Heidelberg Engineering
Mainline Instruments
Mainline Optical Connections
Diopsys
Specialised Ophthalmic Services
Easyscan
Norville Group
 
Go to Forums
Go to Events
 
Login
Back to Suppliers Guide
 
Diopsys_Early Detection_Enhanced Patient Management.jpg

Do you diagnose and manage glaucoma,
diabetic retinopathy, or optic neuritis?1-3

As the world leader in modern visual electrophysiology, Diopsys, Inc. has done more than any other company to advance the use of electroretinography (ERG) and visual evoked potential (VEP) in the eye care practice. The company’s unique, patented technology provides eye care professionals with objective, functional information about the health of the vision system to aid in the early detection of vision disorders, and post-treatment tracking for enhanced patient management. Results from these tests are not just for rare diseases, but also for the management of more common disorders like glaucoma, diabetic retinopathy, optic neuritis, and retinal concerns obscured by media opacities.1-4

Learn More Button.png

Three platforms. Complete visual electrophysiology suite.

We understand that not all eye care practices are the same. Therefore, we provide three unique platforms for our advanced suite of visual electrophysiology modules. The Diopsys® NOVA™ (cart), Diopsys® ARGOS™ (tabletop), and the Diopsys® RETINA PLUS™ (carry case) ERG and VEP Vision Testing Systems allow you to perform multiple visual electrophysiology tests right in your clinical practice. All with intuitive, clear test results that are color-coded based on documented reference ranges.

Diopsys® ERG (pattern electroretinography)

  • Measures performance of retinal ganglion cells
  • Helps identify “stressed” cells at a subclinical stage, when the cells have become dysfunctional but are still alive5

Diopsys® mfERG (multifocal electroretinography)

  • Helps recognize the first signs of drug-induced retinopathy
  • May indicate retinal dysfunction without structural abnormalities6-8

Diopsys® ffERG / Flicker (flicker electroretinography)

  • Indicates level of retinal function loss and recovery on patients with retinopathies9-10
  • Ability to measure the effect of retinopathies on vision through the presence of cataracts.4

Diopsys® VEP (visual evoked potential)

  • Provides objective information on the function of the entire vision system, from the anterior segment of the eye to the visual cortex

Learn how to integrate these exciting technologies into your daily practice.

Learn More Button.png

Diopsys-ARGOS-Homescreen-1024x955.jpg
 
Diopsys-ERG-Contrast-Sensitivity-Glaucoma-1024x955.jpg

1 Banitt et al. Progressive Loss of Retinal Ganglion Cell Function Precedes Structural Loss by Several Years in Glaucoma Suspects. Invest. Ophthalmol. Vis. Sci. 2013;54(3):2346-2352. 2 Pescosolido et al. Role of Electrophysiology in the Early Diagnosis and Follow-Up of Diabetic Retinopathy. J Diabetes Res 2015 5;2015:319692. 3 Naismith et al. Optical coherence tomography Is less sensitive than visual evoked potentials in optic neuritis. Neurology. 2009 Jul 7;73(1):46-52. 4. Ratanapakorn T, et al. Effect of cataract on electroretinographic response. J Med Assoc Thai. 2010 Oct;93(10):1196-9. 5. Ventura LM, et al. The Relationship between Retinal Ganglion Cell Function and Retinal Nerve Fiber Thickness in Early Glaucoma. Invest Ophthalmol Vis Sci. 2006;47:3904–3911. 6. Dettoraki M, Moschos MM. The Role of Multifocal Electroretinography in the Assessment of Drug-Induced Retinopathy: A Review of the Literature. Ophthalmic Res 2016;56:169–177. 7. Talamini CL, et al. Abnormal multifocal ERG findings in patients with normal-appearing retinal anatomy. Doc Ophthalmol 2011;123(3):187-192. 8. Marmor, M, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016;123:6:1386-1394. 9. Yasuda S, et al. Flicker electroretinograms before and after intravitreal ranibizumab injection in eyes with central retinal vein occlusion. Acta Ophthalmol. 2015;93:e465-8. 10. Holm K, et al. Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema. Doc Ophthalmol. 2015;131:43-51.
The Diopsys® NOVA™ is an electrophysiology device that generates photic stimuli, and records, processes, and analyzes the resultant signals to provide information about the visual system. Diopsys Vision Testing Systems carry the CE mark; are FDA 510(k) cleared; and IEC 60601 Certified
© Diopsys, Inc. 2018. All Rights Reserved.